Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study
- 325 Downloads
This study was designed to evaluate expression and prognostic significance of runt-related transcription factor (RUNX)-2 in human nonsmall cell lung cancer (NSCLC). RUNX2 expression was examined at mRNA and protein levels by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot in NSCLC tissues and adjacent normal tissues. In addition, RUNX2 expression was analyzed by immunohistochemistry in 121 clinicopathologically characterized NSCLC cases. The relationship between the expression of RUNX2 and clinicopathological characteristics and prognosis was statistically analyzed. Both qRT-PCR and Western blot demonstrated that RUNX2 mRNA and protein levels were significantly higher in NSCLC tissues compared to the adjacent normal tissues from the same individual. Immunohistochemistry analysis showed that RUNX2 expression was significantly correlated with tumor size, tumor stage, and lymph node metastasis. Higher RUNX2 expression was associated with shorter postoperative survival time of NSCLC patients by Kaplan–Meier method and was found to be an independent risk factor that influences the postoperative survival time of NSCLC patients by Cox regression analysis. In conclusion, these data showed that RUNX2 may play an important role in NSCLC tumorigenesis, and RUNX2 might serve as a novel prognostic marker in NSCLC.
KeywordsRUNX2 NSCLC Prognosis
This work was supported by the National Natural Science Foundation of China (No. 81070094 and No. 30972964).
Conflicts of interest
- 5.Slattery ML, Lundgreen A, Herrick JS, Caan BJ, Potter JD, Wolff RK. Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and risk of colon and rectal cancer: additional support for a TGF-β-signaling pathway. Carcinogenesis. 2011;32(3):318–26. doi: 10.1093/carcin/bgq245.PubMedCrossRefGoogle Scholar
- 8.van der Deen M, Akech J, Lapointe D, Gupta S, Young DW, Montecino MA, et al. Genomic promoter occupancy of runt-related transcription factor RUNX2 in osteosarcoma cells identifies genes involved in cell adhesion and motility. J Biol Chem. 2012;287:4503–17. doi: 10.1074/jbc.M111.287771.PubMedCrossRefGoogle Scholar
- 9.Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X, et al. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res. 2009;15:4322–35. doi: 10.1158/1078-0432.CCR-08-3157.PubMedCrossRefGoogle Scholar
- 19.Underwood KF, D'Souza DR, Mochin-Peters M, Pierce AD, Kommineni S, Choe M, et al. Regulation of RUNX2 transcription factor–DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity. J Bone Miner Res. 2012;27:913–25. doi: 10.1002/jbmr.1504.PubMedCrossRefGoogle Scholar
- 20.Lee KN, Jang WG, Kim EJ, Oh SH, Son HJ, Kim SH, et al. Orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) protein negatively regulates bone morphogenetic protein 2-induced osteoblast differentiation through suppressing runt-related gene 2 (Runx2) activity. J Biol Chem. 2012;287:18888–99. doi: 10.1074/jbc.M111.311878.PubMedCrossRefGoogle Scholar
- 24.Lee SH, Che X, Jeong JH, Choi JY, Lee YJ, Lee YH, et al. Runx2 protein stabilizes hypoxia-inducible factor-1α through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes. J Biol Chem. 2012;287:14760–71. doi: 10.1074/jbc.M112.340232.PubMedCrossRefGoogle Scholar